News
Check out our latest corporate updates, features in the media, and scientific publications and presentations.
Press Releses
Media
Presentations & Publications
- Predina et al, Molecular Therapy 2021
Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic Activity - Kieran et al, Neuro-Oncology 2019
Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma - Aggarwal et al, Molecular Therapy 2018
Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion - Speranza et al, Neuro-Oncology 2018
Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma - Wheeler et al, Neuro-Oncology 2016
Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma - Aguilar et al, Cancer Immunology, Immunotherapy 2015
Gene‑mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma
Candel Therapeutics Appoints Pharma Veteran and Immunologist Paul-Peter Tak, M.D., Ph.D., as Chief Executive Officer; Expands Leadership Team With Chief Financial Officer, Chief Business Officer and Chief Regulatory Officer Appointments
Press ReleaseCandel Therapeutics Announces Presentation of Clinical Data for GMCI in NSCLC at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting
Press ReleaseCandel Therapeutics Announces Presentation at the 2020 American Society of Gene and Cell Therapy (ASGCT) 23rd Annual Meeting
Press ReleaseCandel Therapeutics acquires next-generation herpes drug development platform and manufacturing expertise
Press Release